Download presentation
Presentation is loading. Please wait.
Published byDominick McBride Modified over 3 years ago
1
Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies Xiao-Jun Huang M.D. Ph.D. Peking University Institute of Hematology, Peking University People’s Hospital & Beijing Key Laboratory of HSCT, Beijing, P.R.China
2
1 1 Education Clinic Research
3
The Cumulative Hematopoietic Stem Cell Transplantation (HSCT) Cases of PUIH PUIH The Largest HSCT center in Asia Now >400 cases of HSCT per year Now >60% Allo-HSCT cases are Unmanipulated Haploidentical HSCT 24%
4
Current Clinical Results Strategy to Improve the Clinical Results Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies 1 1 In vitro T-cell-depleted HSCT 2 2 Non-Myeloablative Haploidentical HSCT 3 3 Unmanipulated Myeloablative Haploidentical HSCT
5
GIAC protocol G: donor treatment with rhG-CSF I: intensified immunological suppression A: anti-human thymocyte immunoglobulin (ATG) for the prevention of GVHD C: combination of G-PB and G-BM Huang XJ, et al. Blood, 2006, 107(8):3065-3073 Huang XJ, et al. Annals of Medicine, 2008, 40,444-455 Huang XJ, et al. Clin Cancer Res. 2009;15:4777-4783 Huang XJ, et al. BBMT. 2011 Jun;17(6):821-30. 3. Unmanipulated Haploidentical HSCT
6
Effects of G-CSF on Bone Marrow in Healthy Donors HuangXJ, et al. Clin Transplant 2011: 25: 13–23 3. Unmanipulated Haploidentical HSCT
7
Immunoregulatroy Effects after G-CSF Administration to Healthy Donors Huang XJ, et al. Biol Blood Marrow Transplant.2011;17(2):197-204 3. Unmanipulated Haploidentical HSCT
8
Engraftment Huang XJ, et al. Biol Blood Marrow Transplant,2009, 15(5):632-8 n=348 P=0.008 n=348 CD34+ cells≥2.19×10 6 /kg CD34+ cells<2.19×10 6 /kg P<0.0001 Early stage Advanced stage 3. Unmanipulated Haploidentical HSCT
9
Characteristics of the Allo-Grafts Summary Statistics TNC 10 8 /kg CD34+ ×10 6 /kg CD3+ ×10 8 /kg CD4+ ×10 7 /kg CD8+ ×10 7 /kg CFU-GM ×10 5 /kg BM Range 1.2 ~ 8.30.2 ~ 8.80.1 ~ 1.10.4 ~ 7.30.3 ~ 3.7 1.3~9.4 Median3.531.390.201.101.082.62 PB Range 1.9 ~ 9.20.6 ~ 6.6 1.9 ~ 39.02.9 ~ 29.7 1.4~10.5 Median4.021.581.468.767.013.03 T Range5.2~14.20.8 ~ 13.40.8 ~ 6.73.3~39.63.7~29.62.2 ~ 19.9 Median7.562.651.7710.397.875.21 Huang XJ, et al. Bone Marrow Transplant, 2006, 38:291 3. Unmanipulated Haploidentical HSCT
10
Huang XJ, et al. Biol Blood Marrow Transplant 2009, 15(2) Huang XJ, et al. Biol Blood Marrow Transplant 2011; 17(6) Cumulative incidence of aGVHD after HLA-mismatched allo-HSCT Haplo=81 Identical=36 P=0.11 3. Unmanipulated Haploidentical HSCT
11
Probability of aGVHD with locus disparity Huang XJ, et al. Bone Marrow Transplant. 2006;38(4):291-7. 3. Unmanipulated Haploidentical HSCT
12
DFS & OS compared with HLA Matched Donor Huang XJ, et al. Blood, 2006, 107(8):3065-3073 3. Unmanipulated Haploidentical HSCT
13
Relapse compared with Unrelated Donor ( URD ) Huang XJ, et al. Clin Cancer Res, 2009, 15:4777-4783 PMRD=219 URD=78 PMRD=160 URD=60 3. Unmanipulated Haploidentical HSCT
14
Relapse compared with Identical Sibling ( ISD ) HuangXJ, et al. Biol Blood Marrow Transplant. 2011;17(6) Haplo=81 Identical=36 3. Unmanipulated Haploidentical HSCT
15
OS & DFS compared with ISD PMRD=81 ISD=36 P = 0.048 P = 0.029 HuangXJ, et al. Biol Blood Marrow Transplant. 2011;17(6) Haplo=81 Identical=36 3. Unmanipulated Haploidentical HSCT
16
Superior Graft-versus-Leukemia effect Haploidentical HLA-identical sibling High risk acute leukemia High risk acute leukemia HuangXJ, et al. Biol Blood Marrow Transplant. 2011 ;17(6):821-30 3. Unmanipulated Haploidentical HSCT
17
No. of Haploidentical HSCT accumulated in PUIH PUIH data 3. Unmanipulated Haploidentical HSCT
18
The changing of Composition of Haploidentical allo-HSCT in PUIH from 2007 to 2009 PUIH data 3. Unmanipulated Haploidentical HSCT
19
Studies on HLA-mismatched/haploidentical stem cell transplantation (GIAC) Patie nts (n) DiseaseConditioning GVHD prophylaxis aGHVDcGVHDTRMRelapseLFSReference 35 AML/ALL/CML /DLBCL/ ATL Standard intensity±TBI Tacrolimus based 56%19%11 pt9 pt40% Ichinohe et al. (2004) 171 ALL/AML/CML /MDS Bu/Cy/Ara- C/MeCCNU+ CsA/MTX/M MF 55%21.3% 19% SR @ 2yrs SR 12% SR 68% @ 2yrs Huang et al. (2006) 135 ALL/AML/CML /MDS Bu/Cy/Ara- C/MeCCNU+ATG CsA/MTX/M MF (II-IV) 40% 55%22%18% 64% @ yrs Lu et al. (2006) 68 AML/ALL/CML /MDS/ TBI/Cy/FluCy/MMF/(II-IV)5% * 4% @ 100 days 51% @ 1 yr 34% @ 1yr Luznik et al. (2008) 29 AML/ALL/CML /NHL/ Flu/Mel/OKT3/thio tepa CD3/CD19 depletion (II-IV) 48% 3 pt 20% @ 100 days 12 pt 35% @ 1yr Bethge et al. (2008) 42AML/ALL/CML Bu/Cy/Ara- C/MeCCNU+ATG CsA/MTX/M MF 57.2%27.2% 20.4±6.5% @ 1yr 21.43% 57.3±8% @ 3yrs Liu et al. (2008) 93CML Bu/Cy/Ara- C/MeCCNU+ CsA/MTX/M MF 64.25%27.16%28.3% @ 1yrCP1 3.77% 76.5% @ 1yr Huang et al. (2008) 45 AML/ALL/CML /NHL TBI/Cy/Ara-C/ATG CsA/MTX/M MF/ (II-IV)9 pt3 pt11 pt24 pt Wang et al. (2009) 46AML/CML/ALLTBI/Cy/Ara-C/ATG CsA/MTX/M MF (I-II)10.9%8.7% @ 2yrs 23.9% @ 2yr 70.6% @ 2yrs Chen et al. (2009) 250AML/ALL Bu/Cy/Ara- C/MeCCNU+ ATG CsA/MTX/M MF 45.8%31.3% AML 11.9% @ 3yrs AML 19.4% @ 3yrs AML70.7 %3yrs Huang et al. (2009)
20
Composition of HSCT Donor Types in 24 Transplant Units in China PUIH collected Mis %29.9%30.0%33.6%30.8%30.3%26.5%29.7%29.3% 3. Unmanipulated Haploidentical HSCT
21
Huang XJ, et al. BMT, 2006, 38:291 Huang XJ, et al. Blood, 2006, 107(8):3065-3073 Huang XJ, et al. Clin Cancer Res, 2009, 15: 4777-4783 Huang XJ, et al. BBMT. 2011 Feb;17(2):197-204 Part I Conclusions G-BM combined with PBSC from haploidentical family donors, without in vitro TCD, may be used as a good source of stem cells for allo-HSCT There is no difference in OS and LFS between patients receiving allografts from PMRD and URD 3. Unmanipulated Haploidentical HSCT
22
Huang XJ, et al Unpublished , Blood Reversed
23
Part II : Strategy to Improve the Clinical Results 1 1 Modified Donor Lymphocyte Infusion(DLI) 2 2 Manipulating the Graft 3 3 Optimize KIR ligand match/mismatch 4 4 Improve Immune Reconstitution 3. Unmanipulated Haploidentical HSCT
24
Relapse Remains a Problem after HSCT High risk leukemia Huang XJ et al, Biol Blood Marrow Transplant. 2009 Feb;15(2) Especially for advanced leukemia (58%- 74%) 3. Unmanipulated Haploidentical HSCT
25
Strategy-1 Our modified DLI G-CSF primed peripheral blood progenitor cells instead of steady donor lymphocyte harvests G-CSF primed peripheral blood progenitor cells instead of steady donor lymphocyte harvests Short-term CsA/MTX for prevention of DLI-associated GVHD Short-term CsA/MTX for prevention of DLI-associated GVHD GPBSCI Huang XJ et al, LEUKEMIA, 2006 ; 20 , 365-368 Huang XJ et al, Bone Marrow Transplant. 2009;44(5):309-16 3. Unmanipulated Haploidentical HSCT
26
GVHD prophylaxis Reduced GVHD occurrence Huang XJ, et al. Hematologica, 2007,92:414-417 None MTX 3. Unmanipulated Haploidentical HSCT
27
Prevention of relapse using modified DLI can significantly increase survival following HLA- mismatched/Haplo-identical HSCT in patients with advanced-stage, acute leukemia 3. Unmanipulated Haploidentical HSCT Huang XJ,et al. Bone Marrow Transplant. 2011 Sep accepted
28
DiagnosisN=75 Jan,2003 - Sep,2010 AML N=42 >CR27 NR+REL35 ALL N=33 >CR28 NR+REL25 Patients Characteristic 3. Unmanipulated Haploidentical HSCT
29
Prophylactic GPBPCI Performed at 70 (20 ~ 314) d after HSCT MNC 1.0 (0.5-2.0) 10 8 /kg CD3+ 0.93 (0.2-2.12) 10 8 /kg No patients had profound and lasting pancytopenia after the prophylactic infusion 3. Unmanipulated Haploidentical HSCT
30
Cumulative incidence of grade Ⅲ to Ⅳ acute GVHD GVHD prophylaxis < 2w: 49.5% GVHD prophylaxis 2 ~ 4w: 31.6% GVHD prophylaxis 4 ~ 6w: 14.4% GVHD prophylaxis >6w: 9.3% The risk factor of DLI-associated acute GVHD Huang XJ,et al. Bone Marrow Transplant. 2011 Sep accepted 3. Unmanipulated Haploidentical HSCT
31
Cumulative incidence of aGVHD Huang XJ,et al. Bone Marrow Transplant. 2011 Sep accepted P=0.55 3. Unmanipulated Haploidentical HSCT
32
Cumulative incidence of cGVHD Huang XJ,et al. Bone Marrow Transplant. 2011 Sep accepted P=0.42 3. Unmanipulated Haploidentical HSCT
33
Cumulative incidence of TRM Huang XJ,et al. Bone Marrow Transplant. 2011 Sep accepted P=0.95 3. Unmanipulated Haploidentical HSCT
34
Cumulative incidence of relapse Huang XJ,et al. Bone Marrow Transplant. 2011 Sep accepted P=0.018 3. Unmanipulated Haploidentical HSCT
35
Probability of OS Huang XJ,et al. Bone Marrow Transplant. 2011 Sep accepted (P=0.013) 3. Unmanipulated Haploidentical HSCT
36
Lower relapse rate, a similar NRM, and a higher survival probability compared with non-DLI Can significantly increase the survival of patients with advanced-stage, acute leukemia even after HLA-mismatched, T-cell-replete HSCT Modified prophylactic DLI after HLA-mismatched/Haplo-identical HSCT Huang XJ,et al. Bone Marrow Transplant. 2011 Sep accepted 3. Unmanipulated Haploidentical HSCT
37
Risk stratification-directed DLI could reduce relapse of standard-risk acute leukemia after allo-HSCT Institute of Hematology Peking University Beijing, China ASH 2111 Oral Presentation
38
Efficacy of intervention Groups 3yr-Relapse TRMOSLFS A 18.1% 19.7% 66.0% 61.6% B 68.0% 11.2% 23.9% 20.8% C 29.8% 15.6% 55.4% 52.5% ASH 2111 Oral Presentation
39
Strategy-1 Conclusion m-DLI can be used for the treatment and prophylaxis of relapse after haplo-identical HSCT 3. Unmanipulated Haploidentical HSCT
40
p=0.005 p=0.00017 p=0.001 ( n=12 ) ( n=17 ) ( n=12 ) HuangXJ , et al, Eur J Immunol. 2011 Feb;41(2):514-26 Predictive value of Th17 cells and Tc17 cells in allo-graft on acute GVHD
41
Treating donor mice with rhIL-11 and rhG-CSF promotes transplant- tolerance and preserves the effects of GVL after allogeneic bone marrow transplantation HuangXJ, et al. Leuk Res. 2009 Jan;33(1):123-8 Effects of different cytokines treatment on the recipients’ T cells proliferation activity in response to host alloantigens +14 d after BMT.
42
Strategy-2 Conclusion We may decrease the incidence of GVHD by manipulating the cell contents or function of graft? Mobilization with IL- 11 plus G-CSF ? 3. Unmanipulated Haploidentical HSCT
43
Strategy-3 KIR ligand match/mismatch to outcome on pretransplantation category aGVHD TRM Relapse OS KIR mismatch KIR match Huang XJ, et al. Biol Bone Marrow Transplant, 2008,14(3)
44
Strategy-3 Conclusion KIR ligand mismatch is associated with higher aGVHD, a greater relapse rate, and inferior survival in our haploidentical GIAC protocol---Donor Slection ? 3. Unmanipulated Haploidentical HSCT
45
ALC-30 > 300/ul ALC- 30≤300/ul P<0.001 n=206 Strategy-4 Immune Reconstitution Huang XJ, et al. Bone Marrow Transplant, 2009,43: 29-36 TRM 3. Unmanipulated Haploidentical HSCT ALC-30>300/ul ALC-30≤300/ul
46
** The counts of reconstituted CD3+ cells (cells/μl ) were significantly lower in HLA- mismatched patients at days 30 than those in HLA-matched patients, which reached normal level at days 60 in both HLA-matched and -mismatched patients. ** P < 0.001 HuangXJ, J Cli Imm Online Publication Comparison of Reconstituted T cells subgroup between HLA match and mismatch
47
** ** The counts of reconstituted CD4+ cells (cells/μl ) were significantly lower in HLA- mismatched patients at days 30, 60, 90, and 120 than those in HLA-matched patients, which did not reached normal level until 360 in both HLA-matched and mismatched patients, respectively. * P < 0.05, ** P < 0.001 HuangXJ, J Cli Imm Online Publication Comparison of Reconstituted T cells subgroup between HLA match and mismatch
48
Strategy-4 Conclusion Novel approach to improve the recovery of immune reconstitution are greatly required. IL-2 after HSCT ? A Randomized Clinical Trial Is Undergoing For Evaluing IL-2 After Haplo-identical HSCT In PUIH 3. Unmanipulated Haploidentical HSCT
49
Acknowledgements Stem cell collection center Hai-Yin Zheng Hong Xu Qing Zhao Su Wang Department of Bone Marrow Transplant Dai-Hong Liu Feng-Rong Wang Huan Chen Jing-Zhi Wang Kai-Yan Liu Lan-Ping Xu Wei Han Xiao-Hui Zhang Yu-Hong Chen Yu Wang Laboratory of PUIH Dan Li Ya-Zhen Qin Yan-Rong Liu Yue-Yun Lai
Similar presentations
© 2018 SlidePlayer.com Inc.
All rights reserved.
Ppt on two point perspective drawings Ppt on cloud computing benefits Best ppt on earth day Ppt on social contract theory definition Ppt on global warming and acid rain Ppt on tata trucks Ppt on male reproductive system Ppt on inhabiting other planets that could support Ppt on different domains of the earth Ppt on magnets and springs